OnabotulinumtoxinA  	OnabotulinumtoxinA  	 JJ	B-NP
treatment  	treatment  	 NN	I-NP
of  	of  	 IN	O
mild  	mild  	 JJ	O
glabellar  	glabellar  	 JJ	B-NP
lines  	lines  	 NNS	I-NP
in  	in  	 IN	O
repose  	repose  	 JJ	B-NP
OnabotulinumtoxinA  	OnabotulinumtoxinA  	 NN	I-NP
is  	is  	 VBZ	O
an  	an  	 DT	O
established  	established  	 JJ	O
treatment  	treatment  	 NN	O
for  	for  	 IN	O
glabellar  	glabellar  	 JJ	B-NP
frown  	frown  	 JJ	I-NP
lines 	lines 	 NNS	I-NP
,  	,  	 ,	O
but  	but  	 CC	O
its  	its  	 PRP$	O
effects  	effects  	 NNS	O
on  	on  	 IN	O
lines  	lines  	 NNS	O
at  	at  	 IN	O
repose  	repose  	 NNS	O
are  	are  	 VBP	O
less  	less  	 RBR	O
well  	well  	 RB	O
documented 	documented 	 VBN	O
.  	.  	 .	O
To  	To  	 TO	O
assess  	assess  	 VB	O
the  	the  	 DT	O
effect  	effect  	 NN	O
of  	of  	 IN	O
onabotulinumtoxinA  	onabotulinumtoxinA  	 JJ	O
on  	on  	 IN	O
elimination  	elimination  	 NN	O
of  	of  	 IN	O
mild  	mild  	 JJ	O
lines  	lines  	 NNS	O
at  	at  	 IN	O
repose 	repose 	 NN	O
.  	.  	 .	O
Data  	Data  	 NNS	O
from  	from  	 IN	O
two  	two  	 CD	O
randomized 	randomized 	 NN	O
,  	,  	 ,	O
double-blind 	double-blind 	 NNP	B-NP
,  	,  	 ,	O
placebo-controlled  	placebo-controlled  	 JJ	O
studies  	studies  	 NNS	O
were  	were  	 VBD	O
included 	included 	 VBN	O
.  	.  	 .	O
Elimination  	Elimination  	 NN	O
of  	of  	 IN	O
mild  	mild  	 JJ	O
lines  	lines  	 NNS	O
at  	at  	 IN	O
repose  	repose  	 NN	O
was  	was  	 VBD	O
defined  	defined  	 VBN	O
as  	as  	 IN	O
change  	change  	 NN	O
from  	from  	 IN	O
mild  	mild  	 JJ	O
to  	to  	 TO	O
none  	none  	 NN	O
on  	on  	 IN	O
the  	the  	 DT	O
Facial  	Facial  	 NNP	O
Wrinkle  	Wrinkle  	 NNP	O
Scale 	Scale 	 NNP	O
.  	.  	 .	O
Analysis  	Analysis  	 NNP	O
included  	included  	 VBD	O
183  	183  	 CD	O
participants  	participants  	 NNS	B-NP
who  	who  	 WP	O
received  	received  	 VBD	O
20  	20  	 CD	O
U  	U  	 NNP	O
of  	of  	 IN	O
onabotulinumtoxinA  	onabotulinumtoxinA  	 JJ	O
and  	and  	 CC	O
64  	64  	 CD	O
participants  	participants  	 NNS	B-NP
who  	who  	 WP	O
received  	received  	 VBD	O
placebo 	placebo 	 CD	O
,  	,  	 ,	O
all  	all  	 DT	O
with  	with  	 IN	O
mild  	mild  	 JJ	O
lines  	lines  	 NNS	O
at  	at  	 IN	O
repose  	repose  	 NN	O
at  	at  	 IN	O
baseline 	baseline 	 NN	B-NP
.  	.  	 .	O
Participants  	Participants  	 NNS	B-NP
were  	were  	 VBD	O
evaluated  	evaluated  	 VBN	O
7 	7 	 CD	O
,  	,  	 ,	O
30 	30 	 CD	O
,  	,  	 ,	O
60 	60 	 CD	O
,  	,  	 ,	O
90 	90 	 CD	O
,  	,  	 ,	O
and  	and  	 CC	O
120  	120  	 CD	O
days  	days  	 NNS	O
posttreatment 	posttreatment 	 VBD	O
.  	.  	 .	O
Compared  	Compared  	 VBN	O
to  	to  	 TO	O
placebo 	placebo 	 VB	O
,  	,  	 ,	O
onabotulinumtoxinA-treated  	onabotulinumtoxinA-treated  	 JJ	B-NP
participants  	participants  	 NNS	I-NP
were  	were  	 VBD	O
significantly  	significantly  	 RB	O
more  	more  	 RBR	O
likely  	likely  	 JJ	O
to  	to  	 TO	O
have  	have  	 VB	O
their  	their  	 PRP$	O
lines  	lines  	 NNS	O
at  	at  	 IN	O
repose  	repose  	 VBG	O
eliminated  	eliminated  	 VBN	O
at  	at  	 IN	O
each  	each  	 DT	O
study  	study  	 NN	B-NP
day 	day 	 NN	I-NP
;  	;  	 :	O
[ 	[ 	 -LRB-	O
odds  	odds  	 NNS	B-NP
ratios  	ratios  	 VBP	I-NP
ranged  	ranged  	 VBN	O
from  	from  	 IN	O
42.7  	42.7  	 CD	O
( 	( 	 -LRB-	O
95 	95 	 CD	O
%  	%  	 NN	O
confidence  	confidence  	 NN	B-NP
interval  	interval  	 NNS	I-NP
( 	( 	 -LRB-	O
CI 	CI 	 NNP	O
) 	) 	 -RRB-	O
=12.9-141.9 	=12.9-141.9 	 CD	O
)  	)  	 -RRB-	O
at  	at  	 IN	O
day  	day  	 NN	O
30  	30  	 CD	O
to  	to  	 TO	O
4.9  	4.9  	 CD	O
( 	( 	 -LRB-	O
95 	95 	 CD	O
%  	%  	 NN	O
CI=2.2-10.8 	CI=2.2-10.8 	 CD	O
)  	)  	 -RRB-	O
at  	at  	 IN	O
day  	day  	 NN	O
120  	120  	 CD	O
( 	( 	 -LRB-	O
p  	p  	 JJ	O
< 	< 	 SYM	O
.0001  	.0001  	 NN	O
at  	at  	 IN	O
each  	each  	 DT	O
day 	day 	 NN	O
) 	) 	 -RRB-	O
] 	] 	 -RRB-	O
.  	.  	 .	O
The  	The  	 DT	O
highest  	highest  	 JJS	O
response  	response  	 NN	B-NP
rate  	rate  	 NN	I-NP
was  	was  	 VBD	O
observed  	observed  	 VBN	O
at  	at  	 IN	O
day  	day  	 NN	O
30  	30  	 CD	O
( 	( 	 -LRB-	O
68 	68 	 CD	O
% 	% 	 NN	O
) 	) 	 -RRB-	O
.  	.  	 .	O
OnabotulinumtoxinA  	OnabotulinumtoxinA  	 NNP	B-NP
has  	has  	 VBZ	O
demonstrated  	demonstrated  	 VBN	O
the  	the  	 DT	O
ability  	ability  	 NN	B-NP
to  	to  	 TO	O
eliminate  	eliminate  	 VB	O
mild  	mild  	 JJ	O
glabellar  	glabellar  	 JJ	B-NP
lines  	lines  	 NNS	I-NP
at  	at  	 IN	O
repose  	repose  	 NN	O
for  	for  	 IN	O
a  	a  	 DT	O
significant  	significant  	 JJ	O
number  	number  	 NN	O
of  	of  	 IN	O
patients 	patients 	 NNS	O
.  	.  	 .	O
This  	This  	 DT	O
effect 	effect 	 NN	O
,  	,  	 ,	O
albeit  	albeit  	 IN	O
more  	more  	 JJR	O
subtle  	subtle  	 NN	O
than  	than  	 IN	O
the  	the  	 DT	O
effect  	effect  	 NN	O
on  	on  	 IN	O
dynamic  	dynamic  	 JJ	O
or  	or  	 CC	O
more  	more  	 RBR	O
severe  	severe  	 JJ	O
glabellar  	glabellar  	 JJ	B-NP
lines 	lines 	 NNS	I-NP
,  	,  	 ,	O
may  	may  	 MD	O
be  	be  	 VB	O
an  	an  	 DT	O
important  	important  	 JJ	O
treatment  	treatment  	 NN	B-NP
goal  	goal  	 NN	I-NP
for  	for  	 IN	O
patients  	patients  	 NNS	O
who  	who  	 WP	O
seek  	seek  	 VBP	O
a  	a  	 DT	O
smoother  	smoother  	 JJ	O
appearance  	appearance  	 NN	O
at  	at  	 IN	O
repose 	repose 	 NN	O
.  	.  	 .	O
